ARTICLE
23 March 2022

The FTC Remains Focused On Misleading COVID-19 Claims

WT
Winston Taylor

Contributor

Whether you're leading the way, disrupting an industry, entering a new phase of growth, or launching a defining product—we're in the room with you. In the action. Sleeves rolled up.

With a rich history spanning both sides of the Atlantic, we are present in the major commercial centers that matter to our clients: the U.S., the U.K., Europe, Latin America, and the Middle East. Combining scale with the speed clients demand, our defining capabilities include major litigation, critical transactions, strategic IP, and private wealth.

Our team of over 1,400 lawyers works hand-in-hand across markets, sectors, practice areas, and client teams. All-in problem solvers, we bring the creativity to think differently, and the pragmatism to get things done when it counts the most.

Embedded in your business and sharing your ambition, we take the work personally. Shaping what we do and how we do it around your goals and needs, always one step ahead of the moment.

In 2020, the Federal Trade Commission ("FTC") sent letters to a number of direct sellers, alleging that they or members of their sales force had made false or misleading health and earnings claims related to COVID-19.
United States Consumer Protection

In 2020, the Federal Trade Commission (“FTC”) sent letters to a number of direct sellers, alleging that they or members of their sales force had made false or misleading health and earnings claims related to COVID-19. Then in 2021, Congress enacted the COVID-19 Consumer Protection Act (the “Act”), providing for civil penalties of up to $46,517 for every misleading claim about the treatment, cure, prevention, or mitigation of COVID-19. And just recently, many of our direct selling clients received letters from the FTC reminding them of the FTC's authority under the Act.

Although these “reminder” letters do not seek actual penalties, they demonstrate the FTC is actively monitoring the direct sales channel and searching for the right opportunity to strike. In fact, since the enactment of the Act, the FTC has taken an aggressive stance in targeting those companies and their distributors who attempt to capitalize on COVID-19 and its effects. The FTC is sending a clear message to direct sellers that they must not only monitor their field to identify misleading COVID-19 claims, but they must also act swiftly to remove the claims and impose appropriate corrective measures to deter future claims considered by the FTC to be problematic.

If your company does not currently have a system for identifying misleading distributor earnings and product claims (which of course includes claims made regarding COVID-19), you should consider implementing one right away. And if your company has a system in place, now is a good time to review the system to ensure it is effectively identifying problematic claims. A system is not much help if it is identifying massive amounts of false hits, or if it fails to sweep in terms of interest to the FTC. Most systems, however, can be swiftly optimized by tweaking the search criteria, which is something we routinely help our direct sales clients accomplish.

Ultimately, you want to show the FTC that you have an effective compliance system that identifies and addresses misleading claims. More importantly, ensuring your system is operating efficiently can minimize the risk that the FTC will set its sights on your company in the first place. If you need guidance implementing a system or want assistance with better optimization, we can help.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More